Agile Therapeutics Inc expected to post a loss of $3.70 a share - Earnings Preview

Agile Therapeutics

10/08/2022 03:04

* Agile Therapeutics Inc  AGRX.OQ   AGRX.O  is expected
to show a
rise in quarterly revenue when it reports  results on August
11. 
    * The Princeton New Jersey-based  company is expected to
report  a
67.2% increase in revenue to $1.981 million from $1.19 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Agile Therapeutics
Inc is
for a loss of $3.70 per share. For the same quarter last year,
the company reported a loss of $8.00 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".​
    * Wall Street's median 12-month price target for Agile
Therapeutics Inc is $3​, above​ its last closing price of $0.68.
​​​

This summary was machine generated August 10 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated